ERBB2 and breast cancer: Receptor status remained a significant predictor of the specific site of DM in our study, which agrees with previous studies; specifically, ER+ and HER2- BCs were significantly associated with an increased risk of bone as the first site of DM, whereas ER- BC was significantly associated with brain metastasis [13,36,37,38].